Hopman Mark 4

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), reported a sale of 1,258 shares on June 24, 2026. The reported sale price was $15.01 per share (weighted average $15.0083), for a transaction value of roughly $18,880. The filing classifies the trade as an open‑market or private sale (Form 4, transaction code S). This was a sale (not a purchase), and thus typically considered routine rather than a bullish insider buy signal.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely).
• Shares sold: 1,258. Reported per-share price: $15.01; weighted average price: $15.0083. Price range: $15.00–$15.015.
• Reported proceeds: approximately $18,880 (per filing rounding).
• Footnote F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025 (pre‑arranged plan).
• Footnote F2: The filing gives a weighted average and price range; full per-price share breakdown is available upon SEC or shareholder request.
• Shares owned after the transaction: not provided in the supplied filing details.

Context
A 10b5-1 plan indicates the sale was executed under a pre-established trading arrangement, which often means the transaction was planned in advance and not a direct signal about the insider’s view of the company. For retail investors, purchases are generally more informative about insider conviction than routine sales; this filing documents a routine, pre‑planned sale rather than a spontaneous insider purchase.